New research from the International Neuroendocrine Tumour Consortium has developed a novel precision oncology framework, for the systematic prioritisation of drugs targeting mechanistic tumour dependencies in individual neuroendocrine tumour patients. The work was published in the last issue of Nature Genetics.
Imperial College is one of 18 organisations that make up the Consortium. Chair in Endocrine Surgery, Professor Andrea Frilling, who leads the European Neuroendocrine Tumor Society Centre of Excellence for Neuroendocrine Tumours at Imperial tells us more about the centre and their research.
We have a comprehensive clinical program and several basic research projects with translational aims. We see more than 150 new patients a year and about 1200 follow-up patients, with various types of neuroendocrine tumours; many of them in very advanced tumour stages.
Our research is aiming to provide personalised medicine to our patients. We are working on identification of “omic” based novel tumour markers, which would allow early and accurate tumour diagnosis, selection of treatment based on specific patient and tumour characteristics (one-to-one principle rather than one-for-all), monitoring of treatment response and early detection of disease recurrence.
We have participated in the planning and design of the study, have provided most of the bio samples (tissue, bloods), clinical information and have critically analysed the outcome.
Find out more about the research published in Nature Genetics: A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.